Suppr超能文献

维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:数据与疗效综述

Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy.

作者信息

Iacono Pierluigi, Da Pozzo Stefano, Varano Monica, Parravano Mariacristina

机构信息

IRCCS-Fondazione Bietti, Via Livenza 3, 00198 Rome, Italy.

TSRetina, 34121 Trieste, Italy.

出版信息

Pharmaceuticals (Basel). 2020 Oct 29;13(11):349. doi: 10.3390/ph13110349.

Abstract

Central serous chorioretinopathy represents the fourth most frequent retinal disorder, occurring especially in young age. Central serous chorioretinopathy is mainly characterized by macular serous retinal detachment and although the clinical course moves frequently toward a spontaneous resolution, the subretinal fluid may persist for a long time, thus evolving to the chronic form, and leading to a potential damage of the retinal pigment epithelium and to photoreceptors. The photodynamic therapy with verteporfin plays an important role in the armamentarium among the many therapeutic options employed in this complex retinal disorder. In this review, the authors aim to summarize data of efficacy and safety of PDT focusing especially on mechanisms of action of the PDT and providing comparative outcomes with the alternative therapeutic approaches, including especially the subthreshold laser treatment.

摘要

中心性浆液性脉络膜视网膜病变是第四常见的视网膜疾病,尤其好发于年轻人。中心性浆液性脉络膜视网膜病变主要特征为黄斑区浆液性视网膜脱离,尽管临床病程常趋向于自发缓解,但视网膜下液可能长期持续存在,进而演变为慢性形式,并导致视网膜色素上皮和光感受器的潜在损害。在这种复杂视网膜疾病所采用的众多治疗选择中,维替泊芬光动力疗法在治疗手段中发挥着重要作用。在本综述中,作者旨在总结光动力疗法的疗效和安全性数据,特别关注光动力疗法的作用机制,并提供与其他治疗方法(尤其是阈下激光治疗)的对比结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/7692681/9edca1578c49/pharmaceuticals-13-00349-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验